- Home
- ISPC vs QLGN Comparison
ISPC vs QLGN Comparison
Compare ISPC & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- QLGN
- Stock Information
- Founded
- ISPC 2009
- QLGN 1996
- Country
- ISPC United States
- QLGN United States
- Employees
- ISPC N/A
- QLGN N/A
- Industry
- ISPC Precision Instruments
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- QLGN Health Care
- Exchange
- ISPC Nasdaq
- QLGN Nasdaq
- Market Cap
- ISPC 3.1M
- QLGN 2.8M
- IPO Year
- ISPC 2021
- QLGN N/A
- Fundamental
- Price
- ISPC $0.94
- QLGN $3.54
- Analyst Decision
- ISPC
- QLGN
- Analyst Count
- ISPC 0
- QLGN 0
- Target Price
- ISPC N/A
- QLGN N/A
- AVG Volume (30 Days)
- ISPC 51.4K
- QLGN 9.1K
- Earning Date
- ISPC 08-05-2025
- QLGN 08-13-2025
- Dividend Yield
- ISPC N/A
- QLGN N/A
- EPS Growth
- ISPC N/A
- QLGN N/A
- EPS
- ISPC N/A
- QLGN N/A
- Revenue
- ISPC $8,058,631.00
- QLGN N/A
- Revenue This Year
- ISPC $35.93
- QLGN N/A
- Revenue Next Year
- ISPC N/A
- QLGN N/A
- P/E Ratio
- ISPC N/A
- QLGN N/A
- Revenue Growth
- ISPC N/A
- QLGN N/A
- 52 Week Low
- ISPC $0.86
- QLGN $2.85
- 52 Week High
- ISPC $11.80
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- ISPC 37.62
- QLGN 44.87
- Support Level
- ISPC $0.86
- QLGN $3.37
- Resistance Level
- ISPC $0.97
- QLGN $3.85
- Average True Range (ATR)
- ISPC 0.06
- QLGN 0.23
- MACD
- ISPC -0.02
- QLGN -0.03
- Stochastic Oscillator
- ISPC 18.79
- QLGN 34.29
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.